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doi:10.1Objective: Peroxynitrite, a reactive nitrogen species, has been implicated in the development of ischemia–
reperfusion injury. The present study investigated the effects of the potent peroxynitrite decomposition catalyst
FP15 on myocardial and endothelial function after hypothermic ischemia–reperfusion in a heterotopic rat heart
transplantation model.
Methods: After a 1-hour ischemic preservation and implantation of donor hearts, reperfusion was started after
application of vehicle (5% glucose solution) or FP15 (0.3 mg/kg). The assessment of left ventricular pressure–
volume relations, total coronary blood flow, endothelial function, immunohistochemical markers of nitro-
oxidative stress, and myocardial high-energy phosphates was performed at 1 and 24 hours of reperfusion.
Results: After 1 hour of reperfusion, myocardial contractility (maximal slope of systolic pressure increment at
140 mL left ventricular volume: 5435  508 mm Hg/s vs 2346  263 mm Hg/s), coronary blood flow (3.98 
0.33 mL/min/g vs 2.74 0.29 mL/min/g), and endothelial function were significantly improved, nitro-oxidative
stress was reduced, and myocardial high-energy phosphate content was preserved in the FP15-treated animals
compared with controls.
Conclusions: Pharmacologic peroxynitrite decomposition reduces reperfusion injury after heart transplantation
as the result of reduction of nitro-oxidative stress and prevention of energy depletion and exerts a beneficial ef-
fect against reperfusion-induced graft cardiac and coronary endothelial dysfunction. (J Thorac Cardiovasc Surg
2012;143:1443-9)Ischemia–reperfusion injury is a common problem in car-
diac surgery. Myocardial performance and long-term out-
come are determined by the level of ischemia–reperfusion
injury, especially after heart transplantation with an ex-
tended time of ischemia. Most studies on the effects of myo-
cardial ischemia–reperfusion focus on myocardial injury
and the recovery of contractile function. Recent studies
show the importance of protecting the microvasculature to
attenuate reperfusion injury. Therefore, novel therapeutic
strategies concentrate on management modalities that
prevent both myocardial and endothelial injury during
reperfusion.1,2
The double-faced role of endothelial nitric oxide (NO) in
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Xrecognized. Triggering the synthesis of cyclic guanosine
monophosphate, NO exerts beneficial effects in the cardio-
vascular system, such as vasorelaxation, inhibition of plate-
let aggregation, or protection/preconditioning of the
myocardium.3,4 On the other hand, emerging evidence
supports the role of harmful NO in pathophysiologic
conditions associated with increased nitro-oxidative stress.
Ischemia–reperfusion injury initiates a pathophysiologic
cascade, including an inflammatory response with libera-
tion of reactive oxygen and nitrogen species.1,5 An
extremely toxic nitrogen species, peroxynitrite is formed
by the reaction of NO and superoxide anion radical.
Potential biological actions of peroxynitrite include
cardiac depression, lipid peroxidation, nitration of
tyrosine residues on proteins, inducing DNA strand
breaks, and subsequent activation of the poly(ADP-ribose)
polymerase (PARP) enzyme. PARP initiates an energy-
consuming metabolic cycle by transferring adenosine di-
phosphate (ADP)-ribose units from NADþ to nuclear
proteins. This process results in rapid depletion of intracel-
lular adenosine triphosphate (ATP) pools, eventually lead-
ing to cellular dysfunction and death.6,7
Increased nitrotyrosine (NT) staining (as a footprint of
peroxynitrite) has been reported in experimental cardiac re-
jection in rats8 and humans,9 suggesting that reactive nitro-
gen species (NO or peroxynitrite) may contribute to graft
failure.10 Recent studies have shown that neutralizing
NO11 or peroxynitrite12 directly limits the extent of proteindiovascular Surgery c Volume 143, Number 6 1443
Abbreviations and Acronyms
ADP ¼ adenosine diphosphate
ATP ¼ adenosine triphosphate
CBF ¼ coronary blood flow
dP/dtmax ¼ maximal slope of systolic pressure
increment
LV ¼ left ventricular
LVEDP ¼ left ventricular end-diastolic pressure
LVSP ¼ left ventricular systolic pressure
NO ¼ nitric oxide
NT ¼ nitrotyrosine
PAR ¼ poly(ADP-ribose)
PARP ¼ poly(ADP-ribose) polymerase
PTFE ¼ polytetrafluoroethylene
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Xnitration, prevents PARP activation in rat cardiac trans-
plants, and prolongs graft survival. However, to date there
are few data on the effects of pharmacologic peroxynitrite
decomposition on myocardial and coronary endothelial
function after heart transplantation. Peroxynitrite reacts
rapidly and efficiently with synthetic metalloporphyrins.
One of them, FP15, an N-PEGylated-2-pyridyl iron porphy-
rin, has shown a superior performance as a peroxynitrite de-
composition catalyst.6 The current study investigated the
effect of FP15 on ischemia–reperfusion injury in our well-
established rat model of heterotopic heart transplantation.13MATERIALS AND METHODS
Rat Model of Heterotopic Heart Transplantation
All animals received humane care in compliance with the Principles of
Laboratory Animal Care formulated by the National Society for Medical
Research and the Guide for the Care and Use of Laboratory Animals pre-
pared by the Institute of Laboratory Animal Resources and published by
the National Institutes of Health (Publication No. 86-23, revised 1996).
The experiments were approved by the Ethical Committee of the Land
Baden-W€urttemberg for Animal Experimentation.
According to the model described previously,13 donor rats (young adult
male Lewis rats, 300-350 g) were anesthetized with a single intraperitoneal
injection of ketamine (100 mg/kg) and xylazine (3 mg/kg). After the ab-
dominal cavity was opened, 400 IU/kg sodium heparin was injected into
the inferior caval vein. The abdominal aorta was exposed, and a 1-cm seg-
ment of the infrarenal aorta was occluded by small vessel forceps. A single
intravenous cannula with a polytetrafluoroethylene (PTFE) catheter
(Vygon GmbH & Co, Aachen, Germany) was advanced into the aorta
straight to the aortic arch by shortly opening the upper vessel forceps.
The cannula was removed from the PTFE catheter. Bilateral thoracotomy
was performed, and the heart was exposed. Afterward, cardiac arrest was
induced by injection of 40 mL of cold (4C) histidine-tryptophan-
ketoglutarate solution (Custodiol, Dr Franz K€ohler Chemie GmbH, Als-
bach-H€ahnlein, Germany) at a rate of 20 mL/min using the PTFE catheter.
To reduce the load, the abdominal inferior caval vein was cut. After suc-
cessful induction of cardiac arrest, the superior and inferior caval veins
and pulmonary veins were tied en masse with a 4-0 single silk suture.
The aorta and pulmonary artery were divided, and the heart was immedi-
ately placed into cold histidine-tryptophan-ketoglutarate solution (4C).
The recipient rats (same strain, age, and weight as donors) were1444 The Journal of Thoracic and Cardiovascular Suranesthetized with a single intraperitoneal injection of ketamine (100 mg/
kg) and xylazine (3 mg/kg) and heparinized with 400 IU/kg. The abdomen
was opened by a midline incision, and the aorta and the inferior caval vein
were exposed by reflecting the intestines to the left side. Two-centimeter
segments of the infrarenal aorta and the inferior caval vein were isolated
and occluded by small vessel forceps. The aorta and pulmonary artery of
the donor heart were anastomosed end-to-side to the abdominal aorta
and the inferior caval vein of the recipient rat, respectively. This was
achieved using a 9-0 monofilament polyamide sutures operating under
a 16-powermagnificationmicroscope. Tominimize variability between ex-
periments, the duration of the ischemic period was standardized at 1 hour.
After completion of the anastomoses, the vessels were released and the
heart was then reperfused with blood in situ for 1 or 24 hours.
Nonischemic Heterotopic Heart Transplantation
The technique of ischemic heterotopic heart transplantation was slightly
modified to implant the donor heart without a significant ischemic time. To
ensure a quick implantation of the donor heart, the recipients were specially
prepared before explantation. The animals were heparinized with 400 IU/
kg intravenously. The abdomen was opened by a midline incision, and the
aorta and vena cava were exposed. One-centimeter segments of the infrare-
nal aorta and vena cava were isolated and occluded by small vessel forceps.
Thin polyethylene tubes were inserted via a small incision into the abdom-
inal aorta and inferior caval vein, respectively. The connections were tight-
ened by local application of tissue glue. Afterward, the donor hearts were
explanted as described above. The donor aorta and pulmonary artery were
attached immediately to the corresponding aortic and caval polyethylene
tubes and fixed with 5-0 single silk surgical thread. Then the recipient ves-
sels were released, and the heart was perfused with blood via the polyeth-
ylene tubes for a 1-hour period.
Functional Measurements in the Graft
After 1 or 24 hours of reperfusion, a latex balloon was introduced into
the left ventricle of the graft via the apex and connected to a precision cali-
brated syringe for administration or withdrawal of fluid to determine left
ventricular systolic pressure (LVSP) and left ventricular end-diastolic pres-
sure (LVEDP) and maximal slope of systolic pressure increment (dP/dtmax)
at different left ventricular (LV) volumes by a Millar micromanometer
(Millar Instruments, Inc, Houston, Tex). From these data, LV pressure–
volume relationships were constructed.13 Total coronary blood flow
(CBF) was measured by a perivascular ultrasonic flow probe on the donor
aorta. After baseline measurement, the endothelium-dependent vasodilator
acetylcholine (1 nM, 0.2 mL) and the endothelium-independent vasodilator
sodium nitroprusside (10 nM, 0.2 mL) were administered directly into the
coronary arteries of the graft via the donor aorta. Between the infusions,
CBF was allowed to return to baseline levels. Vasodilator response was ex-
pressed as maximum percent change of CBF from baseline.13
Immunohistochemical Analysis
LV myocardial sections of the grafts were excised for histologic pro-
cessing immediately after completing functional measurements. The tissue
samples were fixed in buffered paraformaldehyde solution (4%) for 1 day
and embedded in paraffin. Adjacent sections were processed for both of the
following types of immunohistochemical labeling. According to the
methods previously described,14 we performed immunohistochemical
staining for NT (marker of nitrosative stress) and poly(ADP-ribose)
(PAR, the enzymatic product of PARP). Primary antibodies used for the
stainings were polyclonal sheep anti-NT antibody (Upstate, Chicago, Ill)
andmousemonoclonal anti-PAR antibody (Calbiochem, SanDiego, Calif).
Quantitative histomorphologic assessment of NT staining was performed
by the COLIM software package (Pictron Ltd, Budapest, Hungary) accord-
ing to the intensity of labeling. The results were expressed with a grading
system of 0 (no staining) to 4 (extensive staining) based on the measured
intensity of positive labeling as described in detail previously.13gery c June 2012
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Transplanted hearts from a separate series of experiments (after 1- or
24-hour reperfusion) were excised and immediately immersed in fluid ni-
trogen (196C) and stored at80C. Myocardial tissue was homogenized
in 3.5%HClO4 and centrifuged at 20,000U/min. The supernatant was neu-
tralized with triethanolamine-HCl/K2CO3 solution. ATP degradation was
assessed with standard photometry using enzyme kinetic assay containing
glycerinaldehyde-3-phosphate-dehydrogenase, 3-phosphoglycerate-kinase,
glycerin-3-phosphate-dehydrogenase, and triosephosphate-isomerase.13
ATP, ADP, and adenosine monophosphate contents were expressed as
micromoles/gram dry weight.
Groups and Experimental Protocol
Four transplant groups were studied (n ¼ 6/each group). Immediately
before releasing the aortic clamp, the slow intravenous injection of 5% glu-
cose solution vehicle (control group) or FP15 (0.3 mg/kg body weight),
a dose comparable to that used in previous studies,5,15 was started and
continued during the first 5 minutes of the reperfusion period. In groups
A (control 1 hour) and B (FP15 1 hour), the measurements of systolic
and diastolic function and CBF were performed after 1 hour of
reperfusion. In groups C (control 24 hours) and D (FP15 24 hours), the
abdominal cavity was closed and the animals were allowed to recover
from the anesthesia. During the following 24 hours, the animals of both
groups received the same standard diet and normal drinking water. After
24 hours, the animals were reanesthetized and the abdominal cavity was
reopened. The grafts were instrumented, and the measurements were
performed as in groups A and B.
In a separate series of experiments, 4 groups (n ¼ 6/each group) of
hearts were transplanted and treated with FP15 or saline vehicle similarly
to the above-mentioned protocol. After 1 or 24 hours of reperfusion, the
grafts were excised to determine high-energy phosphate contents.
The nature of the model and the protocol above allowed the character-
ization of temporal changes in heart function during reperfusion; however,
they did not allow an absolute comparison with preischemic values. To ad-
dress this issue, a modified nonischemic sham-operated transplant group
was investigated (group NI, n ¼ 6) (see above).FIGURE 1. LVSPLVV (A), dP/dtmaxLVV (B), and LVEDPLVV (C) rela
groups. All values are given as mean standard error of the mean (SEM). *P<.0
pressure; LVEDP, left ventricular end-diastolic pressure; LVV, left ventricular v
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All materials used were purchased from Sigma-Aldrich (Taufkirchen,
Germany), unless specified otherwise. FP15 (FeCl tetrakis-2-(triethylene
glycol monomethyl ether) pyridyl porphyrin) was dissolved in 5% glucose
solution vehicle.
Statistical Analysis
All values were expressed as mean  standard error of the mean. Indi-
vidual means between the groups were compared by 1-way analysis of var-
iance followed by an unpaired t test with a Bonferroni correction for
multiple comparisons and the post hoc Scheffe’s test.
RESULTS
Early Reperfusion, 1-Hour, and ‘‘Nonischemic’’
Transplants
Systolic functional recovery was significantly better in
the FP15 group compared with control. LVSP and dP/dtmax
were significantly (P<.05) higher in the FP15 group. Sys-
tolic cardiac function curves showed a significant leftward
shift in the FP15 group compared with the vehicle-treated
group (Figure 1). The values of the ‘‘nonischemic’’ group
were significantly higher compared with the vehicle-
treated transplant group; however, there were no differences
compared with the FP15-treated transplant group. LVEDP
did not differ between the groups. The diastolic compliance
curves (end-diastolic pressure–volume relationships) were
similar in all groups (Figure 1). CBF was significantly
higher (P<.05) in the FP15 group compared with control
after 1 hour (Figure 2, A). Endothelium-independent vaso-
dilatation after sodium nitroprusside (Figure 2, C) was sim-
ilar in both groups. In contrast, endothelium-dependent
vasodilatation after acetylcholine was significantlytionships after heart transplantation and 1 and 24 hours of reperfusion in all
5 control at 1 hour versus every other group. LVSP, Left ventricular systolic
olume.
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FIGURE 2. CBF (A) and vasodilator responses after application of the endothelium-dependent vasodilator acetylcholine (1 nM 0.2 mL, B) and the
endothelium-independent vasodilator sodium nitroprusside (10 nM 0.2 mL, C) after heart transplantation and 1 and 24 hours of reperfusion in all groups.
All values are given as mean  SEM. *P<.05 versus control at a given time point. yP<.05 versus 1 hour. zP<.05 nonischemic versus FP15. ACh, Ace-
tylcholine; CBF, coronary blood flow; SNP, sodium nitroprusside.
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X(P<.05) better in the FP15 group than in the vehicle-treated
transplant group (Figure 2, B). Myocardial high-energy
phosphate content was preserved by FP15 treatment during
heart transplantation (Figure 3), especially ATP content.
Immunohistochemical staining showed increased immu-
noreactivity for NT (diffuse brown staining) and PAR
(dark brown staining in cell nuclei), indicative of nitrosative
stress and enhanced activation of PARP, in the wall ofFIGURE 3. Myocardial total adenylate pool (ATP, ADP, adenosinemono-
phosphate) after heart transplantation and 1 and 24 hours of reperfusion in
the control and FP15 treatment groups. All values are given as mean 
SEM. *P<.05 versus control at a given time point.AMP, Adenosinemono-
phosphate; ADP, adenosine diphosphate; ATP, adenosine triphosphate.
1446 The Journal of Thoracic and Cardiovascular Surintramyocardial blood vessels (especially in the intima
layer) and in the LV myocardium of transplanted hearts of
the control group (Figure 4). FP15 treatment notably
decreased NT immunoreactivity (NT intensity score: 3.1
 0.4 control vs 1.2  0.3 FP15, P<.01) in the myocar-
dium. No PAR immunoreactivity could be detected in the
FP15 treatment group, indicating that FP15 could com-
pletely prevent PARP activation and PAR formation in the
transplanted myocardium. As expected, no immunoreactiv-
ity for NT or PAR could be observed in the ‘‘nonischemic’’
group. Figure 4 shows representative stainings for NT and
PAR in the control and FP15 treatment groups after 1
hour of reperfusion.Late Reperfusion: 24 Hours
After 24 hours of reperfusion, there were no differences
in LVSP (Figure 1, A), dP/dtmax (Figure 1, B), and LVEDP
(Figure 1, C) between the vehicle and the FP15-treated
transplant groups. In the vehicle-treated transplant group,
all these parameters showed a significant improvement
compared with the values after 1 hour of reperfusion
(P<.05). In the FP15-treated transplant group, there were
no significant differences compared with the values of 1
hour of reperfusion. Systolic cardiac function curves
(Figure 1, A and B) and diastolic compliance curves
(Figure 1, C) of the control and FP15 groups were nearly
identical. After 24 hours of reperfusion, CBF was also sim-
ilar in both groups. After 24 hours, endothelium-dependentgery c June 2012
FIGURE 4. Representative immunohistochemical stainings for NT (A, B; brown staining) and (ADP ribose) (C, D; dark brown staining mainly in cell
nuclei) in the myocardium of transplanted hearts after 1 hour of reperfusion in the control (A, C) and FP15 treatment groups (B, D). Magnification:
4003, scale bar: 50 mm.
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Xvasodilatation was significantly increased (P<.05) in both
groups compared with the 1 hour-reperfusion values.
Endothelium-dependent vasodilatation after acetylcholine
was significantly higher in the FP15 group compared with
the vehicle-treated transplant group (Figure 2, B). After
24 hours, total adenylate pool and ATP content showed no
significant differences between the groups (Figure 3).
DISCUSSION
In this study, the benefits of the application of the perox-
ynitrite decomposition catalyst FP15 during reperfusion
were assessed after reversible hypothermic ischemia in
a heterotopic rat heart transplantation model. Heterotopic
heart transplantation was used to simulate the clinical con-
ditions in terms of whole blood reperfusion and to allow an
observation time of 24 hours, which is strongly limited in
isolated organ models. Furthermore, the heterotopic situa-
tion also allows the assessment of myocardial function inde-
pendently of the actual loading conditions. This is the first
study to show that pharmacologic peroxynitrite decomposi-
tion improves myocardial and endothelial functional recov-
ery during early reperfusion and attenuates nitro-oxidative
stress and energy depletion in a clinically relevant heart
transplant model.
During reperfusion after global myocardial ischemia,
high levels of reactive oxidants and free radicals are pro-
duced and are central mediators of reperfusion injury. A po-
tent oxidant species, peroxynitrite (ONOO), is formed by
the reaction of superoxide anion radical (O2
) and the vas-
cular mediator NO and has been established as a pathophys-
iologic relevant endogenous trigger of DNA single-strand
breakage. Peroxynitrite-induced DNA-damage leads to
the activation of nuclear enzyme PARP, which initiates anThe Journal of Thoracic and Carenergy-consuming metabolic cycle by transferring ADP-
ribose units from NADþ to nuclear proteins. This process
results in rapid depletion of intracellular ATP pools, eventu-
ally leading to cellular dysfunction and death.7 Pharmaco-
logic inhibition of PARP has been demonstrated to
improve myocardial and endothelial dysfunction after heart
transplantation in different animal models,13,16 showing the
involvement of the peroxynitrite-PARP pathway in the
pathophysiology of ischemia–reperfusion injury during
heart transplantation. Pharmacologic catalytic decomposi-
tion of peroxynitrite with FP15 has been demonstrated to
effectively eliminate peroxynitrite and prevent PARP acti-
vation both in vitro and in vivo.6,15
As demonstrated in other studies,12,13,17 the present study
showed intensive immunoreactivity for NTand activation of
PARP in the LV myocardium after heart transplantation
(Figure 4), which confirms the increased nitro-oxidative
stress and the activation of the peroxynitrite-PARP pathway
at 2 characteristic levels and is consistent with the above
discussed pathophysiologic processes occurring during
ischemia–reperfusion. Our immunohistochemical data after
FP15 treatment (markedly reduced NT and PAR formation
in the myocardium (Figure 4) indicate the inhibition of the
peroxynitrite-PARP pathway, the main downstream mecha-
nism of nitro-oxidative stress. WW85 (another peroxyni-
trite decomposition catalyst) also has been shown to
decrease nitrosative stress and prevent PARP activation in
an experimental model of acute cardiac rejection,12 which
is consistent with the current study.
On the basis of the results of the present study, we pro-
pose that the decomposition of peroxynitrite by FP15 dur-
ing reperfusion may contribute to a better recovery of the
cellular ATP (Figure 3) and to improved myocardialdiovascular Surgery c Volume 143, Number 6 1447
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mediated by the peroxynitrite-PARP pathway significantly
contributes to endothelial injury in endotoxin shock18 and
diabetes mellitus.19 Thus, improved endothelial function
seen in the FP15 treatment groups might also be explained
by the improved energetic balance of the endothelium.
This is the first study to investigate the effects of the per-
oxynitrite decomposition catalyst FP15 on global hypother-
mic ischemia–reperfusion injury. By comparing our data
after 1 and 24 hours of reperfusion and the data of nonische-
mic transplants, we can conclude that the administration of
FP15 in the given dosewas able to markedly reduce reperfu-
sion injury after a short period of hypothermic preservation.
The reported beneficial cardiac effects of FP15 on global
cardiac ischemia–reperfusion are in agreement with those
of Lauzier and colleagues,20 who demonstrated the cardio-
protective effects of a peroxynitrite decomposition catalyst
after cardioplegic arrest in a working isolated rat heart
model. Likewise, reduced infarct size and ameliorated myo-
cardial damage have been observed after pharmacologic
peroxynitrite decomposition in rodent21 and porcine5 coro-
nary artery ligation (regional ischemia–reperfusion)
models. On the other hand, our control group showed a re-
covery after 24 hours, with similar values to the FP15 group,
suggesting that the applied cardiac preservation time and re-
perfusion only lead to reversible changes of functional status
of the heart. We have compared the data with previous rat
heart transplant studies with similar ischemia–reperfusion
protocols.22-24 On summarizing the data of these studies,
a biphasic recovery pattern is characteristic for this model
with an early phase (<1 hour) followed by a further
improvement during the next 24 hours.
Although enhanced formation of reactive oxidants during
ischemia–reperfusion occurs in both cardiomyocytes and
endothelial cells, leukocyte–endothelial cell interactions
and increased release of oxidants from leukocytes affect
first and foremost mainly the endothelium, resulting in en-
dothelial dysfunction. The damaged dysfunctional coronary
endothelium is responsible for the impaired endothelial vas-
odilatory function of coronary arteries, which limits CBF
leading to impaired cardiac performance. As in our previous
studies, endothelial function was severely impaired after 1
hour of reperfusion and was still depressed in the control
group after 24 hours, as indicated by the lower vasodilatory
response to acetylcholine (Figure 2). The slower recovery of
endothelial function indicates that the coronary endothe-
lium is more vulnerable to reperfusion injury than the myo-
cardium. Accordingly, a previous work demonstrated that
after normothermic ischemia and reperfusion, myocardial
and endothelial function can be dissociated. Although myo-
cardial function showed a full recovery in their model, en-
dothelial function remained impaired.25 The present study
is the first to demonstrate that catalytic peroxynitrite de-
composition improves not only myocardial but also1448 The Journal of Thoracic and Cardiovascular Surendothelial function after heart transplantation. Further-
more, the initial treatment with FP15 has a persisting
long-term beneficial effect on endothelial function
(Figure 2). The observed endothelial effect is comparable
to that with application of NO precursors,23 inosine,24 or
synthetic PARP inhibitors.13 Because pharmacologic elim-
ination of peroxynitrite restores ATP levels, this may con-
tribute to improved endothelial function.
In regard to the improved cardiac and endothelial func-
tion, rapid catalytic decomposition of peroxynitrite by
FP15 in our model seems to be comparable to or better
than the efficacy of blocking the pathway by PARP inhibi-
tion. By eliminating peroxynitrite, nitro-oxidative stress can
be reduced (as demonstrated by our immunohistochemical
data) and severe damage of DNA can be effectively pre-
vented. In addition, by using this concept, peroxynitrite-
induced modifications of enzymes, receptors, and structural
proteins can be avoided and may help to restore the normal
bioavailability of the crucial physiologic mediator NO
(as confirmed by the improved endothelium-dependent
vasodilatation).
On the basis of the data presented in the current report,
we propose that pharmacologic decomposition of peroxyni-
trite represents a potential therapy approach to reduce
ischemia–reperfusion injury during heart transplantation.Limitations
According to the end points assessed, ischemia–
reperfusion injury is a reversible phenomenon in the pres-
ent model. However, the recovery rates of myocardial and
endothelial damage are different. A complete recovery (to
the level of nonischemic controls) of myocardial but not en-
dothelial function has been observed after 24 hours of re-
perfusion, which indicates that the coronary endothelium
is more vulnerable to reperfusion injury than the myocar-
dium. Although the protective effects of peroxynitrite de-
composition at early reperfusion were unequivocally
confirmed, the nature of the present model allows the as-
sessment of longer-term benefits of FP15 only in case of
endothelial damage. A more robust model (eg, longer is-
chemic storage of the donor organ) would be needed to in-
vestigate the long-term effects of FP15 on myocardial
ischemia–reperfusion injury.CONCLUSIONS
Further studies are warranted to provide evidence for
mechanisms on how FP15 may alter endothelial cell
activation, inflammatory cell recruitment, and leukocyte
infiltration.References
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